Gerd Faetkenheuer
About
In The Last Decade
Gerd Faetkenheuer
10 papers receiving 301 citations
Peers
Comparison fields: 5 of 56
- Oncology 167
- Infectious Diseases 106
- Pathology and Forensic Medicine 59
- Virology 59
- Pediatrics, Perinatology and Child Health 55
Countries citing papers authored by Gerd Faetkenheuer
This map shows the geographic impact of Gerd Faetkenheuer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerd Faetkenheuer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerd Faetkenheuer more than expected).
Fields of papers citing papers by Gerd Faetkenheuer
This network shows the impact of papers produced by Gerd Faetkenheuer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerd Faetkenheuer. The network helps show where Gerd Faetkenheuer may publish in the future.
Co-authorship network of co-authors of Gerd Faetkenheuer
This figure shows the co-authorship network connecting the top 25 collaborators of Gerd Faetkenheuer. A scholar is included among the top collaborators of Gerd Faetkenheuer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerd Faetkenheuer. Gerd Faetkenheuer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | More severe infectious complications in CLL patients treated with fludarabine, cyclophosphamide, rituximab (FCR) in comparison to bendamustin plus rituximab (BR): Results of the interim-analysis of the CLL10 trial of the German CLL Study Group | 1 |
| 2 | 5 | |
| 3 | Non-AIDS defining malignancies (NADM) and immunosuppression: The D:A:D study | 2 |
| 4 | 28 | |
| 5 | 44 | |
| 6 | 9 | |
| 7 | 114 | |
| 8 | 18 | |
| 9 | 19 | |
| 10 | 66 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.